A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents

5.4K views

DOI:

10.3791/53879

June 2nd, 2016

* These authors contributed equally

In This Article

Summary

Here we present a protocol for screening of a heptamer-type sgRNA library for potential therapeutic drugs against blood cancers.

Abstract

TRUE gene silencing (termed after tRNase ZL-utilizing efficacious gene silencing) is one of the RNA-directed gene silencing technologies, which utilizes an artificial small guide RNA (sgRNA) to guide tRNA 3′ processing endoribonuclease, tRNase ZL, to recognize a target RNA. sgRNAs can be taken up by cells without any transfection reagents and can downregulate their target RNA levels and/or induce apoptosis in human cancer cells. We have screened an sgRNA library containing 156 heptamer-type sgRNAs for the effect on viability of human myeloma and leukemia cells, and found that 20 of them can efficiently induce apoptosis in at least one of the cancer cell lines. Here we present a protocol for screening of a heptamer-type sgRNA library for potential therapeutic drugs against blood cancers. The protocol includes how to construct the sgRNA library, how to assess the effect of each sgRNA on cell viability, and how to further evaluate the effective sgRNAs by flow cytometry. Around 2,000 hits would be expected to be obtained by screening the full-scale sgRNA library composed of 16,384 heptamers.

Introduction

TRUE gene silencing (termed after tRNase ZL-utilizing efficacious gene silencing) is one of the RNA-directed gene silencing technologies1. This technology has been developed based on properties of tRNase ZL (or 3′ tRNase), tRNA 3′ processing endoribonuclease: it can cleave any target RNA at any expected site under the direction of an artificial small guide RNA (sgRNA) by recognizing a pre-tRNA-like or micro-pre-tRNA-like structure formed between the target RNA and the sgRNA2-9. sgRNA, which is usually 7-31 nt in length, is categorized into four groups, 5′-half-tRNA....

Access restricted. Please log in or start a trial to view this content.

Protocol

1. Construction of a Heptamer-type sgRNA Library

  1. Select a subset of the 16,384 (47) 7-nt sequences unless the full-scale library is to be constructed.
    NOTE: The sequences can be random and/or designed to target specific cellular RNAs. For the latter, find hairpin structures resembling the T-arm of tRNA in a target RNA with the aid of an appropriate computer program and/or visually, and select sequences complementary to 7-nt sequences immediately downstream of the hairpin structures4,10,17,18.
  2. Synthesize each of the selected heptamers as a fully 2′-O-methylated, 5′- and 3′-phosphorylated RNA ....

Access restricted. Please log in or start a trial to view this content.

Results

The six heptamer-type sgRNAs 5′-AUCUUCA-3′ (H1885), 5′-ACACACA-3′ (H3277), 5′-GGGGGCG-3′ (H10927), 5′-GGGGCCC-3′ (H10944), 5′-GCCCCCG-3′ (H12287), and 5′-CACCAGC-3′ (H13260) were chemically synthesized as 2′-O-methyl RNA containing 5′- and 3′-phosphates.

These sgRNAs were examined for the effects on viability of a human leukemia cell line, HL60, and a human myeloma cell line, RPMI-8226. Representative results of the cel.......

Access restricted. Please log in or start a trial to view this content.

Discussion

In most cases, fully 2′-O-methylated, 5′- and 3′-phosphorylated heptamer-type sgRNAs dissolved in water-for-injection-grade water (in the concentration of 100 µM) appear to be stable at below -20 °C for at least one year, judging from their activity to induce apoptosis in cancer cells. However, their stability would change depending on their sequence, quality, and purity. In some cases, 5′- or 3′-phosphate of a part of sgRNA molecules appears to be removed spontaneously du.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

Niigata University of Pharmacy and Applied Life Sciences has a pending patent application on a subset of the heptamer-type sgRNAs.

Acknowledgements

This work was supported by Adaptable and Seamless Technology Transfer Program through Target-driven R&D, Japan Science and Technology Agency, the Science Research Promotion Fund from the Promotion and Mutual Aid Corporation for Private Schools of Japan, and the JSPS KAKENHI Grant Numbers 24300342 and 15H04313.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Custom heptamer RNANippon Bioservice
OligoSep Prep HC CartridgeTransgenomic99-3860
Water-for-injection-grade WaterOtsuka Pharmaceutical 7131400A2129
RPMI-1640 mediumWako189-02025
Fetal Bovine SerumSIGMA-ALDRICH172012-500ML
Penicillin-Streptomycin Mixed SolutionNacalai Tesque26253-84
96 Well PlateGreiner Bio-one655 180
Cell Counting Kit-8DOJINDO343-07623WST-8 solution
Microplate Reader, Sunrise Thermo RC-RTEKAN510-82851
FACS Round-Bottom TubeBD Falcon60819-820
Phosphate Buffered SalineSIGMA-ALDRICHP7059-1L
PE Annexin V Binding BufferBD Biosciences51-66121E
PE Annexin VBD Biosciences51-65875X
7AADSIGMA-ALDRICHA9400-1MG
Flow Cytometer, FACSCaliburBD Biosciences342973

References

  1. Scherer, L., Rossi, J. J. Therapeutic potential of RNA-mediated control of gene expression: Options and designs. RNA and the Regulation of Gene Expression: A hidden layer of complexity. Morris, K. V. , Caister Academic Press. 201-226 (2008).
  2. Nashimoto, M. Conversi....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

Heptamer type sgRNAtRNase ZLCell Viability AssessmentFlow CytometryApoptosis InductionBlood Cancer ScreeningPhosphoramidite Method